Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer.
Date
2024-02-16ICR Author
Author
Coakley, M
Villacampa, G
Sritharan, P
Swift, C
Dunne, K
Kilburn, L
Goddard, K
Pipinikas, C
Rojas, P
Emmett, W
Hall, P
Harper-Wynne, C
Hickish, T
Macpherson, I
Okines, A
Wardley, A
Wheatley, D
Waters, S
Palmieri, C
Winter, M
Cutts, RJ
Garcia-Murillas, I
Bliss, J
Turner, NC
Type
Journal Article
Metadata
Show full item recordAbstract
PURPOSE: Detection of circulating tumor DNA (ctDNA) in patients who have completed treatment for early-stage breast cancer is associated with a high risk of relapse, yet the optimal assay for ctDNA detection is unknown. EXPERIMENTAL DESIGN: The cTRAK-TN clinical trial prospectively used tumor-informed digital PCR (dPCR) assays for ctDNA molecular residual disease (MRD) detection in early-stage triple-negative breast cancer. We compared tumor-informed dPCR assays with tumor-informed personalized multimutation sequencing assays in 141 patients from cTRAK-TN. RESULTS: MRD was first detected by personalized sequencing in 47.9% of patients, 0% first detected by dPCR, and 52.1% with both assays simultaneously (P < 0.001; Fisher exact test). The median lead time from ctDNA detection to relapse was 6.1 months with personalized sequencing and 3.9 months with dPCR (P = 0.004, mixed-effects Cox model). Detection of MRD at the first time point was associated with a shorter time to relapse compared with detection at subsequent time points (median lead time 4.2 vs. 7.1 months; P = 0.02). CONCLUSIONS: Personalized multimutation sequencing assays have potential clinically important improvements in clinical outcome in the early detection of MRD.
Collections
Subject
Humans
Circulating Tumor DNA
Triple Negative Breast Neoplasms
Neoplasm Recurrence, Local
Recurrence
Biomarkers, Tumor
Neoplasm, Residual
Research team
Molecular Oncology
Clin Trials & Stats Unit
Language
eng
Date accepted
2023-12-06
License start date
2024-02-16
Citation
Clinical Cancer Research, 2024, 30 (4), pp. 895 - 903
Publisher
AMER ASSOC CANCER RESEARCH